allylamine has been researched along with Hyperlipoproteinemia Type II in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davidson, M | 1 |
| Hopkins, PN; Karki, S; Marais, AD; Melino, M; Misir, S; Raal, FJ; Schurr, D; Stein, EA; Szamosi, T; Urbina, EM; Xu, J | 1 |
| Perry, CM | 1 |
| Abbink, EJ; Bruckert, E; Durrington, PN; Eriksson, M; Huijgen, R; Imholz, BP; Kastelein, JJ; Schaefer, JR; Stalenhoef, AF; Trip, MD; Visseren, FL | 1 |
| Wilkinson, E | 1 |
2 review(s) available for allylamine and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients.
Topics: Adolescent; Adult; Aged; Allylamine; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Gastrointestinal Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Young Adult | 2013 |
Colesevelam: in pediatric patients with heterozygous familial hypercholesterolemia.
Topics: Allylamine; Anticholesteremic Agents; Bile Acids and Salts; Child; Cholesterol, LDL; Colesevelam Hydrochloride; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Randomized Controlled Trials as Topic | 2010 |
3 trial(s) available for allylamine and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients.
Topics: Adolescent; Adult; Aged; Allylamine; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Gastrointestinal Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Young Adult | 2013 |
Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia.
Topics: Adolescent; Allylamine; Anticholesteremic Agents; Child; Cholesterol, LDL; Colesevelam Hydrochloride; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male | 2010 |
Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial.
Topics: Adolescent; Adult; Aged; Allylamine; Anticholesteremic Agents; Apolipoproteins; Azetidines; Body Mass Index; Cholesterol; Colesevelam Hydrochloride; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Smoking; Triglycerides; Young Adult | 2010 |
1 other study(ies) available for allylamine and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Genzyme's research in cardiovascular disease, putting rare conditions on centre stage.
Topics: Allylamine; Anticholesteremic Agents; Cardiovascular Diseases; Colesevelam Hydrochloride; Drug Industry; Humans; Hyperlipoproteinemia Type II; Rare Diseases | 2010 |